adrenolutin | 87708-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: adrenolutin
• 英文别名: Indole-3,5,6-triol, 1-methyl-；5,6-dihydroxy-1-methyl-2H-indol-3-one
• CAS: 87708-46-1
• 化学式: C₉H₉NO₃
• 分子量: 179.175
• InChiKey: FRBBSLWYVVQVSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  adrenolutin 以 甲醇 为溶剂， 反应 30.0h， 以45%的产率得到5,5',6,6'-tetrahydroxy-1,1'-dimethyl-4,4'-biindolyl-2,2',3,3'-tetrone
  参考文献：
  名称：

  Adrenalin oxidation revisited. New products beyond the adrenochrome stage

  摘要：

  DOI：

  10.1016/s0040-4020(01)89832-x

文献信息

• Process and kit for dyeing hair
  申请人：Bristol-Myers Squibb Company

  公开号：EP0658339A1

  公开（公告）日：1995-06-21

  A process for dyeing hair by preparing and applying to the hair an aqueous reaction medium comprising a dopa species, a reactive direct dye and an oxidant, said aqueous reaction medium optionally containing at least one hair dyeing agent selected from primary intermediates and couplers and also containing a buffer to maintain the pH in the range from 6 to 10 during the reaction, and removing said aqueous reaction medium from the hair within about one hour following its preparation.

  一种染发工艺，通过制备一种水性反应介质并将其涂抹在头发上，该反应介质由多巴物、活性直接染料和氧化剂组成，所述水性反应介质可选择含有至少一种选自初级中间体和偶联剂的染发剂，还含有一种缓冲剂，用于在反应过程中将 pH 值保持在 6-10 之间，并在制备后约一小时内从头发上清除所述水性反应介质。
• 1L1RL-1 as a cardiovascular disease marker and therapeutic target
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：EP2336359A1

  公开（公告）日：2011-06-22

  This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardioivascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

  本发明涉及诊断和治疗心血管疾病的方法和组合物。更具体地说，本发明涉及可用于诊断和/或治疗心血管疾病（包括心脏肥大、心肌梗塞、中风、动脉硬化和心力衰竭）的分离分子。
• PROGNOSIS OF CARDIOVASCULAR DISEASE
  申请人：Critical Care Diagnostics, Inc.

  公开号：EP3059594A1

  公开（公告）日：2016-08-24

  This invention relates to methods for the prediction of the outcome of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.

  本发明涉及预测高体重指数（BMI）人群，如体重指数为 25-29 或 30 或以上，以及肾功能受损人群的心血管疾病（如急性冠状动脉综合征、心力衰竭和/或肺栓塞）预后的方法。
• Epinephrine formulations
  申请人：PAR PHARMACEUTICAL, INC.

  公开号：US10130592B2

  公开（公告）日：2018-11-20

  Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

  包含肾上腺素的药物组合物、给药方法和制造方法。组合物可包含活性剂、pH 值升高剂、抗氧化剂、过渡金属络合剂、pH 值降低剂、补液调节剂中的至少一种，也可选择包含防腐剂和溶剂。
• Sublingual compositions including epinephrine nanoparticles
  申请人：NOVA SOUTHEASTERN UNIVERSITY

  公开号：US10251849B2

  公开（公告）日：2019-04-09

  The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

  本发明提供了包括肾上腺素纳米颗粒的组合物和组合物的治疗使用方法，用于治疗对肾上腺素有反应的病症，如心脏事件或过敏反应，特别是过敏性休克。肾上腺素纳米颗粒可加入口腔崩解剂和快速崩解片剂药物制剂中，可显著提高肾上腺素的舌下生物利用度，从而减少所需的肾上腺素剂量。此外，本发明还提供了用于所述组合物的稳定肾上腺素纳米颗粒的制造方法。